Bio Fluorescent Technologies announces agreement with Immune Network Research Ltd.SCOTTSDALE, Ariz.--(BW HealthWire)--Feb. 12, 1997--Bio Fluorescent Technologies Inc. (BFTI BFTI Brownfields Tax Incentive ) (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:BFTK) Wednesday announced that it has reached an agreement in principle to acquire all of the assets of Immune Network Research Ltd. ("INR INR In currencies, this is the abbreviation for the Indian Rupee. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. "), of Vancouver, British Columbia, Canada, for approximately 9 million BFTI common shares. INR is engaged in the research and development of immunological products for the diagnosis, prevention and treatment of AIDS and other human immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. disorders. Over the past four years, INR has assembled a highly qualified scientific team experienced in advanced research in the treatment of human immune system disorders. Shareholders of both companies should benefit from BFTI's access to the large capital markets for biotechnology companies in the United States and the participation by both companies in the continuing development of INR's assets. The transaction is subject to INR shareholder approval, regulatory approval, satisfactory results from due diligence Research; analysis; your homework. This term has caught on in all industries, because it sounds so "wired." Who would want to do analysis or research when they can do due diligence. See wired. efforts by both companies and finalization of the precise structure of the transaction. CONTACT: Bio Fluorescent Technologies Inc., Scottsdale George, 800/870-1233 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion